Renal sympathetic denervation: Difference between revisions
Joao Silva (talk | contribs) |
Joao Silva (talk | contribs) |
||
| Line 5: | Line 5: | ||
{{SK}} RDN; Renal denervation | {{SK}} RDN; Renal denervation | ||
==Overview== | ==Overview== | ||
'''Renal denervation (RDN)''' is a minimally invasive, [[endovascular]] [[catheter]]-based procedure most commonly using a [[radiofrequency]] energy source, currently aiming to treat [[hypertension]] in selected patients whose [[blood pressure]] isn't controlled with a combination of lifestyle changes and [[antihypertensive|antihypertensive therapy]]. This treatment is based on the fact that these patients have an increase in [[sympathetic]] outflow. <ref name="PapademetriouRashidi2014">{{cite journal|last1=Papademetriou|first1=V.|last2=Rashidi|first2=A. A.|last3=Tsioufis|first3=C.|last4=Doumas|first4=M.|title=Renal Nerve Ablation for Resistant Hypertension: How Did We Get Here, Present Status, and Future Directions|journal=Circulation|volume=129|issue=13|year=2014|pages=1440–1451|issn=0009-7322|doi=10.1161/CIRCULATIONAHA.113.005405}}</ref> By applying [[radiofrequency]] energy pulses to the [[renal arteries]], the [[nerves]] in the [[vessel wall|vascular wall]] ([[adventitia|adventitia layer]]) can be [[ablation|ablated]]. This causes reduction of [[renal]] [[sympathetic]] [[afferent nerve|afferent]] and [[efferent nerve|efferent]] activity with the intent to decrease [[blood pressure]]. <ref>{{cite journal|last=Esler|first=MC|coauthors=Krum, H, Sobotka, PA, Schlaich, MP, Schmieder, RE, Böhm, M|title=Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomized controlled trial.|journal=Lancet|date=2010 Dec 4|volume=376|issue=9756|pages=1903–9|pmid=21093036|doi=10.1016/S0140-6736(10)62039-9}}</ref> Patients with [[resistant hypertension]] are the ones, who despite these changes and taking 3 or more [[antihypertensive drugs]], including a [[diuretic|diuretic drug]], at their maximal tolerated doses, without [[secondary hypertension]], have a baseline [[systolic blood pressure]] of more that 160 mm Hg (or more that 150 mm Hg, in case of concomitant [[type 2 diabetes mellitus]]). <ref name="ThukkaniBhatt2013">{{cite journal|last1=Thukkani|first1=A. K.|last2=Bhatt|first2=D. L.|title=Renal Denervation Therapy for Hypertension|journal=Circulation|volume=128|issue=20|year=2013|pages=2251–2254|issn=0009-7322|doi=10.1161/CIRCULATIONAHA.113.004660}}</ref> Early data from international [[clinical trials]] shows promising results, demonstrating an average [[blood pressure]] reduction of approximately 30mm Hg at three year follow up in patients with [[resistant hypertension|treatment-resistant hypertension]]. <ref name="Symplicity">{{cite journal|last=Symplicity HTN-1|first=Investigators|title=Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months.|journal=Hypertension|date=2011 May|volume=57|issue=5|pages=911–7|pmid=21403086|doi=10.1161/HYPERTENSIONAHA.110.163014}}</ref><ref name="Symplicity_a">{{cite journal|last=Symplicity HTN-2|first=Investigators|coauthors=Esler, MD, Krum, H, Sobotka, PA, Schlaich, MP, Schmieder, RE, Böhm, M|title=Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial.|journal=Lancet|date=2010 Dec 4|volume=376|issue=9756|pages=1903–9|pmid=21093036|doi=10.1016/S0140-6736(10)62039-9}}</ref> Since 2007, over 4000 patients have undergone [[catheter]]-based renal denervation with the Medtronic Symplicity™ Renal Denervation System. <ref name="medtronicrdn">Medtronic. MEDTRONIC SYMPLICITY™ RENAL DENERVATION SYSTEM DEMONSTRATES SIGNIFICANT AND SUSTAINED BLOOD PRESSURE REDUCTION OUT TO THREE YEARS. [Press Release]. Retrieved from: http://www.medtronicrdn.com/pdfs/RDN_ACC_Press_Release_FINAL_03_25_12.pdf. April 4, 2012.</ref> Despite its importance in [[resistant hypertension|drug-resistant hypertensive]] patients, [[renal]] denervation might also be beneficial in other disease states, such as [[congestive heart failure]], [[chronic kidney disease]], [[metabolic syndrome]] and others. <ref name="PapademetriouRashidi2014">{{cite journal|last1=Papademetriou|first1=V.|last2=Rashidi|first2=A. A.|last3=Tsioufis|first3=C.|last4=Doumas|first4=M.|title=Renal Nerve Ablation for Resistant Hypertension: How Did We Get Here, Present Status, and Future Directions|journal=Circulation|volume=129|issue=13|year=2014|pages=1440–1451|issn=0009-7322|doi=10.1161/CIRCULATIONAHA.113.005405}}</ref> | '''Renal denervation (RDN)''' is a minimally invasive, [[endovascular]] [[catheter]]-based procedure most commonly using a [[radiofrequency]] energy source, currently aiming to treat [[hypertension]] in selected patients whose [[blood pressure]] isn't controlled with a combination of lifestyle changes and [[antihypertensive|antihypertensive therapy]]. This treatment is based on the fact that these patients have an increase in [[sympathetic]] outflow. <ref name="PapademetriouRashidi2014">{{cite journal|last1=Papademetriou|first1=V.|last2=Rashidi|first2=A. A.|last3=Tsioufis|first3=C.|last4=Doumas|first4=M.|title=Renal Nerve Ablation for Resistant Hypertension: How Did We Get Here, Present Status, and Future Directions|journal=Circulation|volume=129|issue=13|year=2014|pages=1440–1451|issn=0009-7322|doi=10.1161/CIRCULATIONAHA.113.005405}}</ref> By applying [[radiofrequency]] energy pulses to the [[renal arteries]], the [[nerves]] in the [[vessel wall|vascular wall]] ([[adventitia|adventitia layer]]) can be [[ablation|ablated]]. This causes reduction of [[renal]] [[sympathetic]] [[afferent nerve|afferent]] and [[efferent nerve|efferent]] activity with the intent to decrease [[blood pressure]]. <ref>{{cite journal|last=Esler|first=MC|coauthors=Krum, H, Sobotka, PA, Schlaich, MP, Schmieder, RE, Böhm, M|title=Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomized controlled trial.|journal=Lancet|date=2010 Dec 4|volume=376|issue=9756|pages=1903–9|pmid=21093036|doi=10.1016/S0140-6736(10)62039-9}}</ref> Patients with [[resistant hypertension]] are the ones, who despite these changes and taking 3 or more [[antihypertensive drugs]], including a [[diuretic|diuretic drug]], at their maximal tolerated doses, without [[secondary hypertension]], have a baseline [[systolic blood pressure]] of more that 160 mm Hg (or more that 150 mm Hg, in case of concomitant [[type 2 diabetes mellitus]]). <ref name="ThukkaniBhatt2013">{{cite journal|last1=Thukkani|first1=A. K.|last2=Bhatt|first2=D. L.|title=Renal Denervation Therapy for Hypertension|journal=Circulation|volume=128|issue=20|year=2013|pages=2251–2254|issn=0009-7322|doi=10.1161/CIRCULATIONAHA.113.004660}}</ref> Early data from international [[clinical trials]] shows promising results, demonstrating an average [[blood pressure]] reduction of approximately 30mm Hg at three year follow up in patients with [[resistant hypertension|treatment-resistant hypertension]]. <ref name="Symplicity">{{cite journal|last=Symplicity HTN-1|first=Investigators|title=Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months.|journal=Hypertension|date=2011 May|volume=57|issue=5|pages=911–7|pmid=21403086|doi=10.1161/HYPERTENSIONAHA.110.163014}}</ref><ref name="Symplicity_a">{{cite journal|last=Symplicity HTN-2|first=Investigators|coauthors=Esler, MD, Krum, H, Sobotka, PA, Schlaich, MP, Schmieder, RE, Böhm, M|title=Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial.|journal=Lancet|date=2010 Dec 4|volume=376|issue=9756|pages=1903–9|pmid=21093036|doi=10.1016/S0140-6736(10)62039-9}}</ref> Since 2007, over 4000 patients have undergone [[catheter]]-based renal denervation with the Medtronic Symplicity™ Renal Denervation System. <ref name="medtronicrdn">Medtronic. MEDTRONIC SYMPLICITY™ RENAL DENERVATION SYSTEM DEMONSTRATES SIGNIFICANT AND SUSTAINED BLOOD PRESSURE REDUCTION OUT TO THREE YEARS. [Press Release]. Retrieved from: http://www.medtronicrdn.com/pdfs/RDN_ACC_Press_Release_FINAL_03_25_12.pdf. April 4, 2012.</ref> Despite its importance in [[resistant hypertension|drug-resistant hypertensive]] patients, [[renal]] denervation might also be beneficial in other disease states, such as [[congestive heart failure]], [[chronic kidney disease]], [[metabolic syndrome]] and others. Until now, few [[complications]] have been reported, being inconsequential. It's long-term [[efficacy]] is still yet to be determined, however studies show a permanence of effect at least of 2 to 3 years. <ref name="PapademetriouRashidi2014">{{cite journal|last1=Papademetriou|first1=V.|last2=Rashidi|first2=A. A.|last3=Tsioufis|first3=C.|last4=Doumas|first4=M.|title=Renal Nerve Ablation for Resistant Hypertension: How Did We Get Here, Present Status, and Future Directions|journal=Circulation|volume=129|issue=13|year=2014|pages=1440–1451|issn=0009-7322|doi=10.1161/CIRCULATIONAHA.113.005405}}</ref><ref name="pmid24021387">{{cite journal| author=Schlaich MP, Schmieder RE, Bakris G, Blankestijn PJ, Böhm M, Campese VM et al.| title=International expert consensus statement: Percutaneous transluminal renal denervation for the treatment of resistant hypertension. | journal=J Am Coll Cardiol | year= 2013 | volume= 62 | issue= 22 | pages= 2031-45 | pmid=24021387 | doi=10.1016/j.jacc.2013.08.1616 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24021387 }} </ref> | ||
==History== | ==History== | ||
Revision as of 00:58, 12 April 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2]
Synonyms and keywords: RDN; Renal denervation
Overview
Renal denervation (RDN) is a minimally invasive, endovascular catheter-based procedure most commonly using a radiofrequency energy source, currently aiming to treat hypertension in selected patients whose blood pressure isn't controlled with a combination of lifestyle changes and antihypertensive therapy. This treatment is based on the fact that these patients have an increase in sympathetic outflow. [1] By applying radiofrequency energy pulses to the renal arteries, the nerves in the vascular wall (adventitia layer) can be ablated. This causes reduction of renal sympathetic afferent and efferent activity with the intent to decrease blood pressure. [2] Patients with resistant hypertension are the ones, who despite these changes and taking 3 or more antihypertensive drugs, including a diuretic drug, at their maximal tolerated doses, without secondary hypertension, have a baseline systolic blood pressure of more that 160 mm Hg (or more that 150 mm Hg, in case of concomitant type 2 diabetes mellitus). [3] Early data from international clinical trials shows promising results, demonstrating an average blood pressure reduction of approximately 30mm Hg at three year follow up in patients with treatment-resistant hypertension. [4][5] Since 2007, over 4000 patients have undergone catheter-based renal denervation with the Medtronic Symplicity™ Renal Denervation System. [6] Despite its importance in drug-resistant hypertensive patients, renal denervation might also be beneficial in other disease states, such as congestive heart failure, chronic kidney disease, metabolic syndrome and others. Until now, few complications have been reported, being inconsequential. It's long-term efficacy is still yet to be determined, however studies show a permanence of effect at least of 2 to 3 years. [1][7]
History
Prior to pharmacological management of hypertension, surgical sympathectomy was a recognized treatment for hypertension.[8] This was often successful in reducing blood pressure but due to its non-selective nature the side effects of the procedure were poorly tolerated. Side effects included orthostatic hypotension, palpitations, anhydrosis, intestinal disturbances, loss of ejaculation, thoracic duct injuries and atelactasis.[9] Modern antihypertensive pharmacological interventions have improved the control of hypertension, but an estimated 30% of hypertension cases are resistant. Resistant hypertension is defined as blood pressure above target (140/90mm Hg) despite concomitant use of 3 or more anti-hypertensives – one of which should be a diuretic.[10]
Device
Several devices have been approved for this procedure. One of them is the Symplicity™ Renal Denervation System, produced by Medtronic (formerly Ardian)[11] and consists of an endovascular catheter (6F), radiofrequency generator, dispersive electrodes, foot switch and power cable.[12] In Europe, the Symplicity device received CE mark approval in 2010.[13] The device is available in parts of Europe, Asia, Africa, Australia and the Americas.[6] The Symplicity device currently has over 5 years of clinical experience and 3 years of follow up data. The device has received favourable reviews on WhichMedicalDevice, but concerns have been reported regarding availability and financial reimbursement for the procedure.[14] There are a number of other devices that are currently being evaluated, but these different technologies have limited clinical data and do not have long term data. In addition to Medtronic's Symplicity system, five other renal denervation devices have a CE mark. These include St. Jude Medical’s EnligHTN™ System, Vessix's V2™ Renal Denervation System, Covidien’s OneShot™ System, Recor’s Paradise™ System and Terumo's Iberis™ System. Currently, no renal denervation device has FDA approval today.
Procedure
The Symplicity renal denervation system consists of a generator and a flexible catheter. During this minimally invasive procedure, the interventionalist uses a steerable catheter with a radio frequency (RF) energy electrode tip. The RF energy is delivered to a renal artery via standard femoral artery access. A series of 2-minute ablations are delivered along each renal artery to disrupt the nerves. The procedure does not involve a permanent implant.
Outcomes
The two biggest studies to date have been the Symplicity HTN-1 and HTN-2 trials, conducted with Medtronic's Symplicity RDN System.
Symplicity HTN-1 [4] looked at outcomes in 153 patients that underwent catheter-based renal denervation. Three-year follow-up data have demonstrated an average blood pressure reduction of -33/-19mm Hg.
Symplicity HTN-2 [5] was a randomized, controlled trial that compared 54 control patients with 52 patients who underwent catheter-based renal denervation. Six month follow-up data demonstrated a blood pressure reduction of -32/12mm Hg in the treated group compared with a change of 1/0 mm Hg in the control group. Longer follow-up, more patients, and improved study design are necessary to further validate catheter-based renal denervation. Currently the Symplicity HTN-3 trial is underway in the US. This is a 530-patient, multi-centre, prospective, single-blind, randomized, controlled study (Clinical Trial No. NCT01418261).[15]
Meta-analyses of renal denervation have yielded conflicting results.[16] Whilst office systolic blood pressure reductions typically average around 30 mmHg, reductions observed on ambulatory blood pressure monitoring are typically much smaller, around 10 mmHg.[17] The reasons for this disparity are so far unclear. Proposed theories include renal denervation obliterating the white coat response, thereby disproportionately reducing clinic pressures,[16] or the disparity rather being an anomaly due to deficiencies in renal denervation trial designs to date.[17]
Risks
The Symplicity HTN-1 and HTN-2 trials have demonstrated a good safety profile for catheter based renal denervation. Patients may experience pain during application of radiofrequency pulses and intraprocedural bradycardia requiring atropine has also been reported.[5] Other documented procedure related complications include femoral artery pseudoaneurysm and renal artery dissection.
Of particular concern is the theoretical risk of damage to renal arteries during delivery of radiofrequency energy. An animal study using swine showed no damage to the renal arteries at 6 month follow up. This finding is further supported in human studies in the HTN-1 and HTN-2 trial where follow up imaging has not demonstrated renal vascular damage.[18]
Uses of Renal Denervation beyond Hypertension
Hypertension is associated with an overactive sympathetic drive and renal denervation is the ablation of the renal nerves stopping the cross-talk between the kidneys and brains, thus reducing the sympathetic drive. Similar to hypertension, congestive heart failure (CHF), left ventricular hypertrophy (LVH), atrial fibrillation (AF), obstructive sleep apnea (OSA), and insulin resistance/type 2 diabetes mellitus (DM) all have been associated with an overactive sympathetic drive. Current clinical trials are researching the effect of renal denervation in these clinical conditions as well. [19]
References
- ↑ 1.0 1.1 Papademetriou, V.; Rashidi, A. A.; Tsioufis, C.; Doumas, M. (2014). "Renal Nerve Ablation for Resistant Hypertension: How Did We Get Here, Present Status, and Future Directions". Circulation. 129 (13): 1440–1451. doi:10.1161/CIRCULATIONAHA.113.005405. ISSN 0009-7322.
- ↑ Esler, MC (2010 Dec 4). "Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomized controlled trial". Lancet. 376 (9756): 1903–9. doi:10.1016/S0140-6736(10)62039-9. PMID 21093036. Unknown parameter
|coauthors=ignored (help); Check date values in:|date=(help) - ↑ Thukkani, A. K.; Bhatt, D. L. (2013). "Renal Denervation Therapy for Hypertension". Circulation. 128 (20): 2251–2254. doi:10.1161/CIRCULATIONAHA.113.004660. ISSN 0009-7322.
- ↑ 4.0 4.1 Symplicity HTN-1, Investigators (2011 May). "Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months". Hypertension. 57 (5): 911–7. doi:10.1161/HYPERTENSIONAHA.110.163014. PMID 21403086. Check date values in:
|date=(help) - ↑ 5.0 5.1 5.2 Symplicity HTN-2, Investigators (2010 Dec 4). "Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial". Lancet. 376 (9756): 1903–9. doi:10.1016/S0140-6736(10)62039-9. PMID 21093036. Unknown parameter
|coauthors=ignored (help); Check date values in:|date=(help) - ↑ 6.0 6.1 Medtronic. MEDTRONIC SYMPLICITY™ RENAL DENERVATION SYSTEM DEMONSTRATES SIGNIFICANT AND SUSTAINED BLOOD PRESSURE REDUCTION OUT TO THREE YEARS. [Press Release]. Retrieved from: http://www.medtronicrdn.com/pdfs/RDN_ACC_Press_Release_FINAL_03_25_12.pdf. April 4, 2012.
- ↑ Schlaich MP, Schmieder RE, Bakris G, Blankestijn PJ, Böhm M, Campese VM; et al. (2013). "International expert consensus statement: Percutaneous transluminal renal denervation for the treatment of resistant hypertension". J Am Coll Cardiol. 62 (22): 2031–45. doi:10.1016/j.jacc.2013.08.1616. PMID 24021387.
- ↑ Doumas, M (2009 Apr 11). "Interventional management of resistant hypertension". Lancet. 373 (9671): 1228–30. doi:10.1016/S0140-6736(09)60624-3. PMID 19332354. Unknown parameter
|coauthors=ignored (help); Check date values in:|date=(help) - ↑ Doumas, M (2010 Feb 15). "Renal sympathetic denervation and systemic hypertension". The American journal of cardiology. 105 (4): 570–6. doi:10.1016/j.amjcard.2009.10.027. PMID 20152255. Unknown parameter
|coauthors=ignored (help); Check date values in:|date=(help) - ↑ Calhoun, DA (2008 Jun 24). "Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research". Circulation. 117 (25): e510–26. doi:10.1161/CIRCULATIONAHA.108.189141. PMID 18574054. Unknown parameter
|coauthors=ignored (help); Check date values in:|date=(help) - ↑ WhichMedicalDevice. Symplicity Catheter System (Overview). http://www.whichmedicaldevice.com/by-manufacturer/113/198/symplicity-catheter-system [Accessed online April 5, 2012]
- ↑ Medtronic. RDN Brochure. http://www.medtronicrdn.com/mediakit/RDN%20Brochure.pdf [accessed online 7 April 2012].
- ↑ Medgadget. Medtronic Starts Trial with Symplicity Renal Denervation System for Chronic Heart Failure and Renal Impairment. [Published online 12 Feb 2012] [Accessed online 5 Apr 2012] http://medgadget.com/2012/02/medtronic-starts-trial-with-symplicity-renal-denervation-system-for-chronic-heart-failure-and-renal-impairment.html
- ↑ WhichMedicalDevice. Symplicity Catheter System (User Reviews). http://www.whichmedicaldevice.com/by-manufacturer/113/198/symplicity-catheter-system [Accessed online April 5, 2012]
- ↑ Renal Denervation in Patients With Uncontrolled Hypertension (SYMPLICITY HTN-3). ClinicalTrials.gov Identifier: NCT01418261 http://clinicaltrials.gov/ct2/show/NCT01418261. [Accessed online 7 Apr 2012].
- ↑ 16.0 16.1 http://www.ncbi.nlm.nih.gov/pubmed/22495128
- ↑ 17.0 17.1 http://heart.bmj.com/content/early/2013/09/12/heartjnl-2013-304238.abstract
- ↑ Rippy, MK (2011 Dec). "Catheter-based renal sympathetic denervation: chronic preclinical evidence for renal artery safety". Clinical research in cardiology : official journal of the German Cardiac Society. 100 (12): 1095–101. doi:10.1007/s00392-011-0346-8. PMID 21796327. Unknown parameter
|coauthors=ignored (help); Check date values in:|date=(help) - ↑ www.renaldenervationworld.org